GI Science Summit
TL1A Therapies in IBD — From Bench to Bedside
Friday, October 16, 2026
(12:00 PM CET – 5:00 PM CET)
Experience in-person presentations by subject matter experts.
Alimentiv Presents the GI Science Summit on:
TL1A Therapies in IBD — From Bench to Bedside
Event Overview
This complimentary half-day scientific and educational event will bring together key stakeholders including gastroenterologists, basic & translational scientists, clinical pharmacologists, trialists and industry sponsors.
The Summit has the following objectives:
Conduct an overview and gain further understanding of therapies targeting TL1A, including critical aspects of translational research, clinical pharmacology, clinical research, and early drug development.
Define key objectives required to provide new mechanistic insights into the molecular determinants of efficacy and safety of therapeutics targeting TL1A.
Identify areas of research that can guide treatment strategies and accelerate further drug development in this class of agents.
Lunch will be provided on the day of the event.
Location: Renaissance Barcelona Fira Hotel
Address: Plaza de Europa 50, 08902, Hospitalet de Llobregat, Barcelona, Spain, 08902
Website: https://marriott.com/hotels/bcnrf-renaissance-barcelona-fira-hotel/overview
Summit: Friday, October 16, 2026 | 12:00 PM CET – 5:00 PM CET; Europa 1+2, 1st Floor
Expert Panel
Fabio Cominelli, MD, PhD
Case Western Reserve University
USA
Silvio Danese, MD, PhD
Vita-Salute San Rafaele University
Italy
Randy Longman, MD, PhD
Cornell University
USA
Dermot McGovern, MD, PhD
Cedars-Sinai Medical Center
USA
Margaret Neighbors, PhD
Genentech, Inc.
USA
Bruce Sands, MD, MS
Mount Sinai Health System
USA
Agenda
| 12:00 PM | Registration & Buffet Lunch |
| Session 1: Basic Science and Mechanism of Action | |
| 1:00 PM | Welcome Dr. Vipul Jairath — Alimentiv Inc. & University of Western Ontario, Canada |
| 1:05 PM | Preclinical History of TL1A Dr. Fabio Cominelli — Case Western Reserve University, USA |
| 1:30 PM | Genetics and Drug Discovery of TL1A Dr. Dermot McGovern — Cedars-Sinai Medical Center, USA |
| 1:55 PM | Panel discussion |
| Session 2: IBD Therapies Targeting TL1A | |
| 2:10 PM | Overview of TL1A Trials in IBD and Existing Data on Efficacy and Safety Dr. Silvio Danese — Vita-Salute San Raffaele University, Italy |
| 2:35 PM | TL1A as Target for Fibrosestenosing Crohn’s Disease Dr. Randy Longman — Cornell University, USA |
| 3:00 PM | Panel Discussion |
| 3:15 PM | Break |
| Session 3: Advances and Evolving Treatment Strategies | |
| 3:30 PM | The Latest TL1A Pathway Insights and Clinical Advances Dr. Maggie Neighbors — Genentech, Inc., USA |
| 3:55 PM | Combination Therapy With TL1A as Backbone Dr. Bruce Sands — Mount Sinai Health System, USA |
| 4:20 PM | Panel Discussion |
| 4:30 PM | Meeting Wrap-up |
Meeting Co-Chairs
Vipul Jairath, MBChB, PhD, MRCP, FRCPC
Alimentiv, Inc & University of Western Ontario
Canada
Chris Ma, MD, MPH, FRCPC
Alimentiv, Inc & University of Calgary
Canada
